Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...
In this video, Xiuning Le, MD, PhD, discusses the state of the pipeline for developing EGFR-mutated lung cancer treatments.
The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...
DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...
Celltrion launches ADC cancer drug trials in U.S. while planning additional INDs Celltrion accelerates its global drug ...
Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...
The study is evaluating TUB-030, Tubulis’ next-generation antibody-drug conjugate (ADC), in patients with advanced solid tumors. The ADC targets 5T4, an oncofetal antigen expressed in a broad ...
AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...
Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback